Real Tech Fund, Practical application of blood test kit for immunocompromised schizophrenia / autism, etc.
Invested in "RESVO Co., Ltd." to optimize treatment for intractable diseases

Euglena Investment Co., Ltd.

Euglena Investment Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative: Akihiko Nagata) is a new investment destination for the venture capital fund "Real Tech Fund", a blood test that distinguishes between immunocompromised schizophrenia and autism. We are pleased to inform you that we have invested in RESVO Co., Ltd. (hereinafter referred to as "RESVO"), which develops kits.

　It is said that schizophrenia and autism, which are mental and nervous system diseases, can occur in about 1% of the total population regardless of region or race, but the causes of the onset are diverse. , No clear test method or radical treatment method has been established at present. In particular, basic research suggests that the onset of immunocompromised schizophrenia and autism may be prevented from becoming more severe by appropriate treatment with early intervention, but the onset is due to immune impairment. There was no way to tell if it was a thing.
　Under such circumstances, RESVO discovered a blood biomarker * 1 for immunopathic schizophrenia / autism, and put into practical use a blood test kit for immunopathic schizophrenia / autism that makes use of the discovery. We are conducting research and development for. When this blood test kit is put into practical use, it will be possible to provide care tailored to the symptoms of each patient with immunocompromised schizophrenia and autism, and the QOL (quality of life) * 2 of patients and their families. Can be expected to improve. In addition, RESVO possesses cutting-edge disease proteomics technology * 3, and plans to continue research and development on treatment methods for various intractable diseases.
　This time, the Real Tech Fund will underwrite the shares issued by RESVO through a third-party allotment, and will support the acquisition of subsidies related to research and development and marketing activities.
　The details are as follows.
　* 1 Blood biomarker: A specific biological substance contained in blood that is an indicator of the presence or progression of a disease.
　* 2 QOL (Quality of Life): Quality of life and quality of life from the perspective of society
　* 3 Disease proteomics technology: Technology that comprehensively analyzes changes in proteins in diseases

About investment inRESVO Co., Ltd.

■ About the outline and support contents of RESVO Co., Ltd.
　Date of establishment: January 23, 2015
　Location: 3-15-201 Omorikita, Ota-ku, Tokyo
　Representatives: Representative Director Nobufumi Kobayashi (CEO), Shin Onishi (CTO)
　Fund: 58 million yen (excluding capital reserve)
　Business: Development of blood test kits for immunocompromised schizophrenia and autism
　​HP: http://resvo-inc.com/
　Support content: Support for R & D-related subsidies and marketing activities
　Investment period: May 2017

■ About Realtech Fund (HP: http://www.realtech.fund)
　Our 100% subsidiary of Euglena Investment, SMBC Nikko Securities, Ribanesu "Limited Liability Company was founded three companies Euglena in venture capital funds that SMBC Nikko Ribanesu capital" to management and operation, the investment development of the real tech venture as the main purpose is. With a total of 30 participating companies and a fund size of 9.4 billion yen (as of June 2017), it is Japan's largest fund specializing in real tech. We are investing in and nurturing real tech ventures with the following operating companies that are investors.

Investors: Euglena Investment Co., Ltd., SMBC Nikko Securities Co., Ltd., Revanes Co., Ltd., Nippon Tobacco Industry Co., Ltd., Mitsui Real Estate Co., Ltd., Yoshinoya Holdings Co., Ltd., Rohto Pharmaceutical Co., Ltd., Kanetsu Co., Ltd., Dentsu Co., Ltd., Tokyo Century Kyowa Hakko Kirin Co., Ltd., Aizawa Securities Co., Ltd., Shimizu Construction Co., Ltd., Sumitomo Mitsui Banking Corporation, ANA Holdings Co., Ltd., THK Co., Ltd., Toyo Aluminum Co., Ltd., Daiichi Life Insurance Co., Ltd., CQ Ventures Co., Ltd. , East Japan Passenger Railway Co., Ltd., Nippon Unisys Co., Ltd., JCU Co., Ltd., Toyo Spinning Co., Ltd., Softbank Co., Ltd., Mitsubishi Electric Co., Ltd., AS ONE Co., Ltd., ShinMaywa Industry Co., Ltd. Automobile Co., Ltd. (30 companies in total, as of June 2017)

​ ​

-Contact for inquiries from the press-
Euglena Co., Ltd. Public Relations and IR Division